Teva Pharmaceutical Industries Ltd announced today that the US Food and Drug Administration has approved the company's ANDA for Amoxicillin for Oral Suspension (BID), 200 mg/5 mL and 400 mg/5 mL. A launch date will be determined soon.
Amoxicillin for Oral Suspension is the AB-rated generic equivalent of GlaxoSmithKline's broad spectrum antibiotic Amoxil for Oral Suspension. The brand product has annual sales of approximately $63 million.
Headquartered in Israel, Teva Pharmaceutical Industries is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80 percent of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. — (menareport.com)
© 2002 Mena Report (www.menareport.com)
